Agenus announces Phase II results from gastroesophageal cancer therapy
Patients received induction with agenT-797 (alone or with BOT/BAL) or started the combination without induction.
Clinical Trials
First patient receives JANX014 dose in Janux’s trial for mCRPC
Precision receives CTA approval to expand ELIMINATE-B study
GlycoNex secures Japan’s PMDA approval for GNX1021 Phase I trial
Vir Biotechnology doses first patient in Phase I VIR-5500 trial
AllRock Bio begins patient dosing in Phase IIa ROCSTAR trial
Hemispherian begins Phase I/IIa trial of GLIX1 for GBM
First patient dosed in CatalYm’s Phase IIb visugromab trial
